Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
WASHINGTON, April 11, 2016 -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use of safe and effective regenerative cell therapies in the United States. The April 12th event, Advancing a New Policy Framework for Regenerative Cell Therapy—which begins at 9:30am EST and will be webcast live—will bring together scientific and academic experts, patients, practitioners, and industry to discuss the science behind cell therapy and new policies needed to modernize the current U.S. regulatory approach.
In addition to co-hosting the event, the Regenerative Medicine Foundation is collaborating with BPC to convene and engage a broad societal-based alliance of non-profit patient groups, medical philanthropies, academic centers, industry organizations, and other advocates to support a new regulatory pathway for safe and effective cell therapies in the U.S.
"With the recent introduction of the bipartisan, bicameral REGROW Act, the time has arrived for us to move from laboratories into the clinic," said Bernie Siegel, executive director of the Regenerative Medicine Foundation and founder and chair of the annual World Stem Cell Summit & RegMed Capital Conference. "Cell therapies are different from drugs, and they have the vast potential to alleviate human suffering. We need to support the FDA in accelerating safe and effective cell therapy treatments, and the Regenerative Medicine Foundation is committed to this humanitarian cause."
"We are delighted to be working with the Regenerative Medicine Foundation to advance regenerative cell therapy—which represents one of the most promising areas for the next generation of groundbreaking treatments," said Janet Marchibroda, director of BPC's health innovation initiative. "Through our work together, we are advancing public policy that will accelerate the availability of safe and effective treatments for Americans and improve U.S. competitiveness in the global marketplace."
About the Regenerative Medicine Foundation
The nonprofit Regenerative Medicine Foundation, formerly known as the Genetics Policy Institute, is an influential global network of stakeholders from patient-advocacy, science, and industry that serves as a catalyst and provides leadership to the pro-cures movement. Through RMF's action network, reports, newsletters, the flagship World Stem Cell Summit and RegMed Capital Conference, special projects, speaking engagements, world-renowned advisory boards, educational resources, teaching initiatives, and strategic relationships, RMF serves as the foremost channel of knowledge between leading regenerative medicine experts, patient advocates, and those who make policy for the general public.
CONTACT: Alan Fernandez
650-759-8300
[email protected]
